| Autor: |
Ron, Han G., Mordish, Yair, Eisenthal, Avi, Skornick, Yehuda, Inbar, Moshe J., Chaitchik, Samario |
| Zdroj: |
Cancer Immunology, Immunotherapy; November 1994, Vol. 38 Issue: 6 p379-384, 6p |
| Abstrakt: |
Chemotherapy and interleukin-2 (IL-2) and/or interferon a (IFNa) produce objective responses in a proportion of patients with advanced malignant melanoma. The duration of response to chemotherapy is usually less than 4 months, and immunotherapy has resulted in longlasting remissions in a small number of patients with metastatic melanoma. The current study was conducted to improve the antitumor efficacy and the interactions between recombinant (r) IL-2, rIFNa2a and chemotherapy. A total of 16 evaluable patients with metastatic malignant melanoma were entered into a phase-II study designed to assess the response rate and therapeutic efficacy of dacarbazine and carboplatin followed by rIL-2 and rIFNa2a. Patients received 750 mg/m2 dacarbazine with 400 mg/m2 carboplatin each by intravenous bolus on days 1 and 22. Recombinant IL-2 and IFNa2a were administered on an outpatient basis (home therapy) subcutaneously for 6 consecutive weeks: 4.8×106 IU/m2 rIL-2 daily, 5 days a week; 6.0×106 IU/m2 rIFNa2a thrice weekly. There were responses in 6 of the 16 enrolled patients with an overall response rate of 37.5% (95% confidence interval: 14%–61%). All responding patients had partial responses. The median survival time of the responding patients was significantly better than that of patients with progressive and stable disease (P=0.03). The median duration of response was 11 months (range 2–24 months). Responses in lung, liver, soft tissue and lymph-node sites were noted. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink